Evonik Industries and Dober Chemical Corp. announced today the market launch of two detergents specifically developed for cleaning coating equipment after processing pharmaceutical formulations based on EUDRAGIT® RL/RS and EUDRAGIT®NE/NM. The products, Chematic® RL/RS Cleaner and Chematic® NE/NM Cleaner, were designed to provide higher cleaning efficiency and lower associated process cost. Both detergents will exclusively be marketed by Evonik Industries.
Evonik and cleaning science specialist Dober joined forces to address cleaning challenges associated with the processing of extended release coating systems. The properties of Chematic detergents were specifically designed for sustained release EUDRAGIT® polymers.
Based on customer feedback gathered by Evonik, the new detergents show a nearly 70% reduction in cleaning time. This in turn results in shorter downtime, reduced labor costs and significant energy savings. In addition, the products meet worldwide regulatory requirements and are GMP-compliant.
Dr. Jean-Luc Herbeaux, head of the Health Care business line at Evonik, stated, "Thanks to the collaboration with Dober, we are now able to offer cleaning solutions for EUDRAGIT®, which are superior in terms of safety, effectiveness and cost-efficiency."
Daniel J. Dobrez, Executive Vice-President of Dober, added, "Further to the benefits in terms of time, costs, manpower and energy, these products are truly "user-friendly". This is due to their mild chemistry, low processing temperatures and simple handling procedures."
Evonik will market Chematic® RL/RS Cleaner and Chematic® NE/NM Cleaner to the pharmaceutical and nutraceutical industry. The manufacture and global supply of the products will be handled by Dober. The business partnership combines the expertise of both companies and provides Evonik customers with a truly unique value.
More information about Chematic® RL/RS Cleaner and Chematic® NE/NM Cleaner can be found at www.eudragit.com/cleaning.
Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.6 billion and an operating profit (adjusted EBITDA) of about €2.6 billion.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.